

Zynex Financial Restructuring Puts Company on Path to Long-Term Success

ENGLEWOOD, Colo., Dec. 16, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation today announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring with the support of new financing from the Company's lenders.

"Today we take the next step in creating a new future for Zynex," said Steven Dyson, Chief Executive Officer. "This financing demonstrates the confidence our lenders have in our business and the extensive positive changes we have made in recent months. Paired with our renewed commitment to the highest integrity in our business practices, a financial restructuring puts Zynex on the path to long-term success."

Zynex operations will continue as usual with no impact to patients, customers, or employees.

Dyson added, "We look forward to sharing our progress as we fulfill our mission to improve the quality of life for patients suffering from debilitating pain."

For more information, please visit Zynex's case website: <https://dm.epiq11.com/Zynex>.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to strategies and objectives for future operations; potential outcomes of the evaluation of the strategic alternatives by the Special Committee; and other similar statements.

Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, our ability to identify and complete a transaction as a result of the strategic alternative process; our ability to raise capital or otherwise improve our liquidity position and continue as a going concern; the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; the outcome of the Tricare payment suspension; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, market conditions; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.

These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-

Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation. For additional information, please visit: www.zynex.com.

Investor Relations Contact:

Vikram Bajaj, CFO

ir@zynex.com

Media Relations Contact:

Britt Logan DiGiulio

media@zynex.com

SOURCE Zynex, Inc.

<https://zynexmed.investorroom.com/2025-12-16-Zynex-Financial-Restructuring-Puts-Company-on-Path-to-Long-Term-Success>